FHI 360, the National Department of Health in Papua New Guinea and the U.S. Agency for International Development are hosting trainings that introduce doctors to bedaquiline, the first new drug for tuberculosis in more than 45 years. Daniel Tesfaye, FHI 360 Country Director, says, “It’s important to ensure that people who have multidrug-resistant tuberculosis get the best treatment,” and adds, “FHI 360 is working to register adverse events in the global system so that Papua New Guinea can become a full member of the World Health Organization’s Uppsala Monitoring Centre.”
